Aurinia Pharmaceuticals News and Activities

Presence

Aurinia Pharmaceuticals develops and sells prescription medicines for autoimmune and kidney diseases. Its products and drug research programs serve patients, doctors, and healthcare providers.

Aurinia Pharmaceuticals products and services overview:

Prescription medicines
Autoimmune therapies
Kidney disease treatments
Drug research
Clinical development

Revenue: ~$200 million

Employees: 300

Headquarters: Edmonton, Canada

Aurinia Pharmaceuticals is one of the...

Aurinia Pharmaceuticals is a company listed under the stock ticker AUPH (US).

Acquisition, funding and merger involving Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals has announced the acquisition of Kezar Life Sciences (posted on April 1 2026).

Executives

View the org chart displaying its 22 main executives

Most searched biographies at Aurinia Pharmaceuticals

Popular executive movements at Aurinia Pharmaceuticals

Thomas Wei has joined the company as Chief Scientific Officer (posted on March 23 2026).
Kevin Tang, who was Chairman of the Board, is promoted to Chairman of the Board and Chief Executive Officer (posted on March 23 2026).
Michael Hearne has joined the company as Chief Financial Officer (posted on March 23 2026).

Click here to view some more movements at Aurinia Pharmaceuticals

Create your alert
to follow the executive moves at Aurinia Pharmaceuticals.